Kunming, China

Lin Xu

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lin Xu - Innovator in Antidepressant Research

Introduction

Lin Xu is a notable inventor based in Kunming, China. He has made significant contributions to the field of medicine, particularly in the development of treatments for depression. His innovative approach has led to the creation of a unique patent that showcases his expertise and dedication to improving mental health.

Latest Patents

Lin Xu holds a patent for the "Application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression." This invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives, which have been shown to exhibit more significant antidepressant effects than traditional medications such as fluoxetine or imipramine. The findings from his studies indicate the potential of these compounds in enhancing mental health treatments.

Career Highlights

Throughout his career, Lin Xu has worked with esteemed organizations, including the Chinese Academy of Sciences and Kunming Jingbiao Biosciences R&D Co., Ltd. His work in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Lin Xu has collaborated with notable colleagues, including Jijun Chen and Jun Zhou. These partnerships have further enriched his research and development efforts, leading to advancements in the understanding of antidepressant compounds.

Conclusion

Lin Xu's innovative work in the field of antidepressant research highlights his commitment to improving mental health through scientific advancements. His patent and collaborations reflect his significant contributions to the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…